A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma

International Journal of Radiation Oncology Biology Physics

Volumn 92, Issue 5, 2015, Pages 986-992

  Krauze, Andra V ^a   Myrehaug, Sten D ^b   Chang, Michael G ^c   Holdford, Diane J ^c   Smith, Sharon ^a   Shih, Joanna ^a   Tofilon, Philip J ^a   Fine, Howard A ^d   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LAKERIDGE HEALTH CORPORATION   (Canada)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; ONCOLOGY; RADIATION; REGRESSION ANALYSIS; TOXICITY;

CONCURRENT RADIATION THERAPY; HISTONE DEACETYLASE INHIBITOR; METHODS AND MATERIALS; NATIONAL CANCER INSTITUTE; PROGRESSION FREE SURVIVAL; RADIATION MORBIDITY; RADIATION THERAPY ONCOLOGY GROUPS; RECURSIVE PARTITIONING ANALYSIS;

RADIOTHERAPY;

TEMOZOLOMIDE; VALPROIC ACID; ALKYLATING AGENT; DACARBAZINE; HISTONE DEACETYLASE INHIBITOR; RADIOSENSITIZING AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DRUG BRAIN LEVEL; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GROUPS BY AGE; HEARING DISORDER; HUMAN; HUMAN TISSUE; MALE; METABOLIC DISORDER; MOUSE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; VISUAL DISORDER; ADJUVANT CHEMOTHERAPY; AGE; ANALOGS AND DERIVATIVES; BLOOD; BONE MARROW; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROCEDURES; RADIATION DOSE; RADIATION RESPONSE; TIME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TIME FACTORS; VALPROIC ACID;

EID: 84937429313     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.04.038     Document Type: Article

References (35)

1. R. Stupp, M.E. Hegi, W.P. Mason, and et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
2. C. Senft, A. Bink, K. Franz, and et al. Intraoperative MRI guidance and extent of resection in glioma surgery: A randomised, controlled trial Lancet Oncol 12 2011 997 1003
3. M.R. Gilbert, J.J. Dignam, T.S. Armstrong, and et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 20 2014 699 708
4. C. Nieder, N. Andratschke, N. Wiedenmann, and et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 180 2004 401 407
5. E. Binello, S. Green, and I.M. Germano Radiosurgery for high-grade glioma Surg Neurol Int 3 suppl 2 2012 S118 S126
6. J.D. Waters, B. Rose, D.D. Gonda, and et al. Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma J Neurooncol 113 2013 467 477
7. P.J. Tofilon, and K. Camphausen Molecular targets for tumor radiosensitization Chem Rev 109 2009 2974 2988
8. K. Camphausen, W. Burgan, M. Cerra, and et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275 Cancer Res 64 2004 316 321
9. K. Camphausen, D. Cerna, T. Scott, and et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by VPA Int J Cancer 114 2005 380 386
10. K. Camphausen, T. Scott, M. Sproull, and et al. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation Clin Cancer Res 10 2004 6066 6071
11. P. Chinnaiyan, D. Cerna, W.E. Burgan, and et al. Postradiation sensitization of the histone deacetylase inhibitor VPA Clin Cancer Res 14 2008 5410 5415
12. E. Perucca Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience CNS Drugs 16 2002 695 714
13. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, and et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. P.Y. Wen, D.R. Macdonald, D.A. Reardon, and et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group J Clin Oncol 10 2010 1963 1972
15. R. Stupp, W.P. Mason, M.J. van den Bent, and et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
16. R.O. Mirimanoff, T. Gorlia, W. Mason, and et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2006 2563 2569
17. M.D. Sztajnkrycer Valproic acid toxicity: Overview and management J Toxicol Clin Toxicol 40 2002 789 801
18. T.L. Phillips, V.A. Levin, D.K. Ahn, and et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: A Northern California Cancer Center phase II study Int J Radiat Oncol Biol Phys 21 1991 709 714
19. R.C. Urtasun, D. Cosmatos, J. Del Rowe, and et al. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: A comparison of short versus long intravenous dose schedules (RTOG 86-12) Int J Radiat Oncol Biol Phys 27 1993 207 214
20. L.L. Kleinberg, S.A. Grossman, K. Carson, and et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study J Clin Oncol 20 2002 3149 3155
21. D.F. Nelson, D. Schoenfeld, A.S. Weinstein, and et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study Int J Radiat Oncol Biol Phys 9 1983 1143 1151
22. J. Del Rowe, C. Scott, M. Werner-Wasik, and et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and RT for glioblastoma multiforme J Clin Oncol 18 2000 1254 1259
23. R.O. Miralbell, F. Mornex, R. Greiner, and et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer trial 22933 J Clin Oncol 17 1999 3143 3149
24. A. Lai, A. Tran, P.L. Nghiemphu, and et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme J Clin Oncol 29 2011 142 148
25. J.D. Hainsworth, K.C. Shih, G.C. Shepard, and et al. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma Clin Adv Hematol Oncol 10 2012 240 246
26. M.D. Prados, W.M. Wara, P.K. Sneed, and et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme Int J Radiat Oncol Biol Phys 49 2001 71 77
27. R. Stupp, P.Y. Dietrich, S. Ostermann Kraljevic, and et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 2002 1375 1382
28. A. Chakravarti, M. Wang, H.I. Robins, and et al. RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients Int J Radiat Oncol Biol Phys 85 2013 1206 1211
29. P.D. Brown, S. Krishnan, J.N. Sarkaria, and et al. North Central Cancer Treatment Group study N0177. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme. North Central Cancer Treatment Group study N0177 J Clin Oncol 26 2008 5603 5609
30. D.M. Peereboom, D.R. Shepard, M.S. Ahluwalia, and et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme J Neurooncol 98 2010 93 99
31. M.D. Prados, S.M. Chang, N. Butowski, and et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J Clin Oncol 27 2009 579 584
32. M.R. Rosenfeld, M.C. Chamberlain, S.A. Grossman, and et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma Neuro Oncol 12 2010 1071 1077
33. N. Butowski, S.M. Chang, K.R. Lamborn, and et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma Neuro Oncol 13 2011 1331 1338
34. M. Weller, T. Gorlia, J.G. Cairncross, and et al. Prolonged survival with VPA use in the EORTC/NCIC temozolomide trial for glioblastoma Neurology 77 2011 1156 1164
35. C.A. Barker, A.J. Bishop, M. Chang, and et al. Valproic acid use during radiation therapy for glioblastoma associated with improved survival Int J Radiat Oncol Biol Phys 86 2013 504 509